Zealand Pharma Shares Fall Amid Resurfaced Concerns Over Drug Trial Dropout Rates
Zealand Pharma's shares declined significantly as data revealed that nearly one in five patients discontinued the late-stage survodutide trial for obesity due to gastrointestinal side effects. These high dropout rates are reigniting investor concerns.